Verification of the Benefits of Strategic Shareholdings and Voting Policies
First written in FY2018. 3 of 8 entries say "Restated". Latest entry: FY2026.
- FY2026AdvancedAnnual report
「During the fiscal year, the Company continued to hold shares of TERUMO CORPORATION, its principal supplier and the largest holding by balance sheet carrying amount, after comprehensively considering the status of the shares being pledged as collateral to TERUMO CORPORATION and other factors.」
The Company reviewed its policy-held shares each fiscal year and sold shares of 1 company, while continuing to hold shares of its principal supplier, TERUMO CORPORATION, in light of the status of the shares being pledged as collateral and other factors. - FY2024RestatedAnnual report
「In addition, each fiscal year, the Board of Directors considers whether to continue holding or reduce each policy-held shareholding, comprehensively taking into account its economic rationale, future prospects and the status of any use as collateral.」
The policy of reviewing policy-held shares each fiscal year, individually by issue, based on their economic rationale, future prospects and status as collateral, among other factors, remains in place. - FY2023Sale of 1 Cross-ShareholdingAnnual report
「Based on the results of the above review, the Company sold shares of 1 company during the fiscal year.」
The Company continues to review each holding individually every fiscal year and successively sell shares whose quantitative benefits have declined, and sold shares of 1 company during the fiscal year. - FY2022RestatedAnnual report
「Based on the results of the above review, the Company sold shares of 2 companies during the fiscal year.」
The Company continues to review policy-held shares each fiscal year and successively sell holdings whose quantitative benefits have declined, and sold shares of 2 companies during the year. - FY2021AdvancedAnnual report
「Based on the results of the above review, the Company sold shares of 2 companies during the fiscal year.」
Based on its policy of reviewing policy-held shares each fiscal year, the Company sold shares of 2 companies during the fiscal year. The policy of successively selling holdings whose quantitative benefits have declined also remains in place. - FY2020SoftenedAnnual report
「Because the quantitative benefits of holding some shares have declined, the Company has adopted a policy of selling them successively going forward.」
The policy on policy-held shares has been made more specific, with plans to sell successively certain holdings whose quantitative benefits have declined. - FY2019RestatedAnnual report
「The Company holds shares of business partners and companies in the same industry as policy-held shares for purposes other than pure investment when it expects to maintain or develop a business relationship over the medium to long term, or when the shares are deemed strategically important, such as for business expansion. Each fiscal year, the Board of Directors individually verifies the benefits and necessity of each holding and reviews whether it should be retained.」
The policy of limiting policy-held shares to those necessary for business relationships and business strategy, and verifying each holding individually every fiscal year, remains in place. - FY2018First statedAnnual report
「The Company will continue to hold only those policy-held shares that are deemed necessary from a policy perspective after comprehensively considering their contribution to improving the corporate value of the Group over the medium to long term, as well as the relevance and importance of the business relationship and business strategy. Each year, the Company will review whether to continue holding the shares after verifying the benefits and necessity of the holdings.」
The Company has stated for the first time its policy of limiting policy-held shares to those necessary for its business strategy and verifying the benefits and necessity of the holdings each year, as well as its policy of exercising voting rights in light of the investee's sustainable growth and medium- to long-term enhancement of corporate value.